{"brief_title": "Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection", "brief_summary": "Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Thymopentin"], "criteria": "Inclusion Criteria Concurrent Treatment: Allowed: - Aerosolized pentamidine. Prior Medication: Allowed: - Aerosolized pentamidine. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - AIDS as defined by the CDC (except for those with HIV \"wasting syndrome\"). - Significant hepatic disease. - Thrombocytopenia (< 75000 platelets/mm3). - Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to entry. - Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. - Known hypersensitivity to thymopentin. Prior Medication: Excluded within 30 days of study entry: - Immunomodulatory or experimental therapy. - Excluded within 90 days of study entry: - Zidovudine (AZT). Patients must not have: - AIDS as defined by the CDC (except for those with HIV \"wasting syndrome\"). - Significant hepatic disease. - Thrombocytopenia (< 75000 platelets/mm3). Patients with the following conditions are included: - Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. - HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions. - HIV \"wasting syndrome\". - Must voluntarily sign consent. History of intravenous drug abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Acquired Immunodeficiency Syndrome", "mesh_term": ["Infection", "Communicable Diseases", "HIV Infections", "Thymopentin"], "id": "NCT00002051"}